DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactOrders & Deals

Aurobindo Pharma Limited — Amalgamation OR Merger-XBRL

NSE 2 hrs ago·5 Aug 2026, 2:49 pm

Aurobindo Pharma

Aurobindo Pharma has informed stock exchanges that it is considering an amalgamation or merger. This corporate restructuring involves combining the company with another entity, likely to create a larger, more competitive player in the market.

For investors, such a move can signal a strategic shift aimed at expanding market share or operational efficiencies. It may also lead to changes in shareholding patterns and corporate governance structures.

Investors should watch for official announcements regarding the target company and the specific terms of the deal. It is crucial to understand how this integration will impact the combined entity's financial performance and long-term growth prospects.